Fifth Annual - Advances in the Diagnosis and Treatment of the Rheumatic Diseases

Ustekinumab, an Inhibitor of IL 12/23, Studied in Patients with Psoriatic Arthritis
- April 3, 2009

There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional non-biologic DMARDs and TNF inhibitors.  Interleukins (IL) 12 and 23 have been implicated in the pathogenesis of plaque psoriasis. 

Disease Outcomes of Early Non-Radiographic Spondyloarthropathy Explored - March 24th, 2009

The spondyloarthropathies (SpA) are a group of related conditions that include ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, the arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy.

Arthritis News